BioCentury | Apr 15, 2013
Clinical News

Tarafenacin: Phase IIb data

...in 234 patients with OAB showed that once-daily 0.2 and 0.4 mg doses of oral tarafenacin...
...week 12, the primary endpoint. Salvat said it plans to conduct Phase III testing of tarafenacin...
...Co. Ltd. (KSE:009290), Seoul, South Korea Laboratorios Salvat S.A. , Barcelona, Spain Product: Tarafenacin (formerly SVT-40776...
BioCentury | Oct 15, 2007
Clinical News

SVT-40776: Completed Phase II enrollment

...332 patients in a double-blind, dose-finding, international Phase II trial to compare 3 doses of SVT-40776...
...N.Y.) markets Detrol LA tolterodine to treat OAB. Laboratorios Salvat S.A. , Barcelona, Spain Product: SVT-40776...
Items per page:
1 - 2 of 2